Clinical trials
Lung Cancer (Locally Advanced or Metastatic) clinical trials
Below are recruiting lung cancer (locally advanced or metastatic) clinical trials, each written for real people, not researchers. We’re tracking 5,847 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07286331RecruitingPhase 3
New drug vs chemo for advanced endometrial cancer
This trial tests a new drug (mocertatug rezetecan) compared to standard chemotherapy for people with endometrial cancer that has progressed after platinum-based chemo and immunotherapy. It may help if your tumor has a protein called B7-H4.
Buenos AiresAges 18 years+ - NCT07286266RecruitingPhase 3
Testing a new drug for platinum-resistant ovarian cancer
This phase 3 trial tests a new drug, mocertatug rezetecan, against standard treatments for ovarian cancer that no longer responds to platinum chemo. It's for people who have had 1 to 4 prior therapies and may offer a new option if you haven't tried all standard treatments yet.
Randwick, New South WalesAges 18 years+ - NCT03001362Recruiting
Wait-and-see treatment for people with rectal cancer
This study tests a “wait-and-see” approach instead of immediate surgery for certain rectal cancers, aiming to avoid unnecessary operations. It may help people who are medically able to stay under close monitoring and only have surgery if needed.
Montreal, QuebecAges 18–90 - NCT03016819RecruitingPhase 3
Test drugs anlotinib and catequentinib for advanced sarcoma
This Phase 3 study tests two anti-cancer medicines (anlotinib and catequentinib) for people with certain advanced soft-tissue sarcomas, including alveolar soft part sarcoma, synovial sarcoma, and leiomyosarcoma. It is designed for tumors that cannot be removed and that have either grown despite treatment or no longer respond to standard options.
Phoenix, ArizonaAges 18 years+ - NCT03053193Recruiting
Testing gene activity to guide breast cancer treatment
This study links breast tumor test results from MammaPrint and optional BluePrint (and full genetic data) with real-world clinical information to understand which new gene activity patterns matter. It may help future patients by improving how doctors use these tests to guide care.
Birmingham, AlabamaAges 18 years+ - NCT03067051RecruitingPhase 1/Phase 2
Test of a prostate cancer light-activated treatment device
This study tests the safety and early effectiveness of the SpectraCure P18 system, which uses light-activated medicine to treat prostate cancer that has come back locally after radiation. It may help some people avoid or delay more invasive treatment, while researchers carefully watch side effects.
New York, New YorkAges 18 years+ - NCT03206060RecruitingPhase 2
Lu-177 DOTATATE for hard-to-remove pheochromocytoma or paraganglioma
This trial studies Lu-177 DOTATATE (Lutathera), a targeted radiation medicine, for tumors that cannot be safely removed with surgery. It aims to shrink or control pheochromocytoma/paraganglioma that is showing recent growth and has a specific target signal on a special PET scan.
Bethesda, MarylandAges 18–100 - NCT03250078Recruiting
Pancreatic cancer screening for people at high genetic risk
This study offers pancreatic cancer screening for people with strong family history or certain inherited gene changes. It may help find pancreatic cancer earlier, when treatment may be more effective.
Norwalk, ConnecticutAges 50–90 - NCT03406247RecruitingPhase 2
Immunotherapy after salvage surgery for head and neck cancer
This Phase 2 trial tests an immunotherapy given after salvage surgery for certain head and neck squamous cell cancers that came back (or a new second cancer) in an area that was already treated with radiation. It aims to lower the chance the cancer returns after surgery, especially in higher-risk situations.
Villejuif, Val De MarneAges 18 years+ - NCT03417622RecruitingPhase 3
Wide vs narrow breast surgery margins after lumpectomy
This study compares two ways of cutting the edge (margin) of tissue during lumpectomy after breast cancer treatment. It may help reduce the chance of the cancer coming back locally by testing whether a wider margin is better than a narrow one.
Al Mansurah, DKAges 18 years+ - NCT03465592RecruitingPhase 1/Phase 2
Nivolumab after mismatched bone marrow transplant for sarcoma
This trial studies nivolumab (an immune treatment) in people with sarcoma who already had a partially mismatched bone marrow transplant. It may help the new immune system recognize and attack cancer, and researchers will also watch closely for side effects like GVHD (immune reaction after transplant) and autoimmune problems.
St. Petersburg, FloridaAges 1–40 - NCT03561740RecruitingPhase 3
Capecitabine plus usual treatment for high-risk HER2 breast cancer
This trial looks at whether adding a chemotherapy medicine called capecitabine (taken in smaller, regular doses) to the standard after-surgery (adjuvant) treatment can lower the chance of cancer coming back in people with early-stage, high-risk HER2-positive breast cancer. It targets patients who still had cancer left after earlier treatment or who had higher-risk tumor features.
Guangzhou, GuangdongAges 18–70 - NCT03581773RecruitingPhase 2
Folic acid to reduce mouth sores during kidney cancer treatment
This Phase 2 trial tests whether folic acid can lessen mucositis (painful mouth sores) caused by certain kidney cancer medicines. You would either take folic acid or an inactive pill, and the study looks for improvement in these side effects.
Aarhus, Central Region of DenmarkAges 18 years+ - NCT03588286Recruiting
Check heart rhythm risk early after a heart attack
This trial tests whether a programmed heart rhythm test can better identify who needs an implanted defibrillator (ICD) soon after a heart attack. It may help prevent dangerous fast heart rhythms (tachyarrhythmias) by guiding who gets an ICD.
Boston, MassachusettsAges 18–85 - NCT03630991RecruitingPhase 1
Calcium chelator medicine for AML or MDS during chemotherapy
This Phase 1 study tests whether edetate calcium disodium (also called succimer) can be safely given to people with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) while they are on chemotherapy. The goal is to learn the safest dose and whether it has signs of helping the blood cancer respond to treatment.
Houston, TexasAges 1 year+ - NCT03667170RecruitingPhase 2
Study drug for certain colon cancers with MSI-H or dMMR
This Phase 2 trial tests KN035 in people with advanced or spread-out tumors that have specific genetic markers (MSI-H or dMMR). If you qualify, the study team will look at how well the drug works and how it affects side effects in that group.
Beijing, Beijing MunicipalityAges 18 years+ - NCT03701581RecruitingPhase 2/Phase 3
4-aminopyridine to help erections after prostate nerve surgery
This trial tests whether a medicine called 4-aminopyridine (4AP) can help recover or protect erectile function after “nerve-sparing” prostate surgery. It’s for men with early-stage, non-spread prostate cancer who are scheduled for robotic prostate surgery and have good baseline erections.
Tucson, ArizonaAges 45–75 - NCT03721068RecruitingPhase 1
CAR T-cell treatment for hard-to-treat childhood tumors
This Phase 1 study tests an experimental CAR T-cell treatment that targets GD2, with added immune-boosting and safety features, for children with relapsed or refractory neuroblastoma or osteosarcoma. It’s designed to see if the treatment is safe and can shrink these cancers when standard therapy hasn’t worked.
Atlanta, GeorgiaAges 1.5 years+ - NCT03760575RecruitingPhase 1
Pembrolizumab plus chemo with surgery for pleural mesothelioma
This trial studies how well pembrolizumab (an immune therapy) works when added to chemotherapy before image-guided surgery for malignant pleural mesothelioma. It aims to shrink or control the cancer and improve surgical results by combining treatments.
Philadelphia, PennsylvaniaAges 18 years+ - NCT03785574Recruiting
Treating hydatidiform mole when lung nodules might be metastasis
This study looks at different treatment approaches for hydatidiform mole when a CT scan shows lung nodules and the team cannot rule out spread. It may help guide the safest next steps and follow-up plan.
Hangzhou, ZhejiangAges Up to 60 years - NCT03800693RecruitingPhase 2
Shorter vs longer oxaliplatin infusions for gut cancer
This Phase 2 study compares giving oxaliplatin by IV for 2 hours versus 6 hours, along with the standard FOLFOX6 chemotherapy. It aims to see if the shorter infusion works as well and is manageable for people with gastrointestinal cancers.
Atlanta, GeorgiaAges 18 years+ - NCT03805022RecruitingPhase 3
Extra chemotherapy around surgery for high-risk soft-tissue sarcoma
This trial tests whether giving stronger chemotherapy before and/or after surgery helps people with high-risk, resectable soft-tissue sarcoma. It aims to lower the chance the cancer comes back by improving treatment around the time of the operation.
BordeauxAges 18 years+ - NCT03858205Recruiting
Low-dose radiation to relieve pain from bone tumors
This trial studies whether low-dose radiation can reduce pain from a specific bone lesion caused by multiple myeloma. It may help people whose main problem is painful bone metastasis, with targeted treatment to the painful spot.
Duarte, CaliforniaAges 18 years+ - NCT03949231RecruitingPhase 3
Infusion immunotherapy through the liver artery for liver cancer
This trial tests a combination of immune “brakes” medicines (PD-1/PD-L1/CTLA-4) delivered through the liver’s artery, to help treat advanced liver cancer. It may help the immune system attack the cancer more effectively, especially if other local liver treatments aren’t possible or have stopped working.
Guanzhou, GuangdongAges 18–80
Hear when a new Lung Cancer (Locally Advanced or Metastatic) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for lung cancer (locally advanced or metastatic)?
- Yes. Clin2 currently lists 5,847 recruiting lung cancer (locally advanced or metastatic) studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a lung cancer (locally advanced or metastatic) trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a lung cancer (locally advanced or metastatic) trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Locally Advanced or Metastatic Non-small Cell Lung Cancer
- Locally Advanced or Metastatic Breast Cancer
- Locally Advanced Non-Small Cell Lung Cancer
- Advanced or Metastatic Non-small Cell Lung Cancer
- Colorectal Cancer (Locally Advanced or Metastatic)
- Liver Cancer (Locally Advanced or Metastatic)
- NSCLC (Advanced Non-small Cell Lung Cancer)
- Non Small Cell Lung Cancer Metastatic
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.